The role of 18F-fluorodeoxyglucose positron emission tomography in thyroid neoplasms

Oncologist

Volumn 16, Issue 4, 2011, Pages 458-466

  Lang, Brian Hung Hin ^a   Law, Tsz Ting ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Fluorodeoxyglucose; Indeterminate cytology; Positron emission tomography; Thyroid carcinoma; Thyroid incidentaloma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; ASPIRATION BIOPSY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFERENTIATED THYROID CARCINOMA; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THYROID FOLLICULAR CARCINOMA; THYROID INCIDENTALOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID TUMOR; THYROIDITIS; METHODOLOGY; PATHOLOGY; REVIEW; SCINTISCANNING; THYROID GLAND; TUMOR RECURRENCE;

FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROID GLAND; THYROID NEOPLASMS; THYROID NODULE;

EID: 79955012481     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0256     Document Type: Article

References (60)

1. Pace L, Nicolai E, Klain M et al. Diagnostic value of FDG PET/CT imaging. Q J Nucl Med Mol Imaging 2009;53:503-512.
2. Wadsak W, Mitterhauser M. Basics and principles of radiopharmaceuticals for PET/CT. Eur J Radiol 2010;73:461-469.
3. Fletcher JW, Djulbegovic B, Soares HP et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480-508.
4. Newberg A, Alavi A, Reivich M. Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders. Semin Nucl Med 2002;32:13-34.
5. Gerber BL, Ordoubadi FF, Wijns W et al. Positron emission tomography using (18)F-fluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: Optimal criteria for the prediction of recovery of post-ischemic left ventricular dysfunction. Results from the European Community Concerted Action Multicenter study on use of(18)F-fluoro-deoxyglucose Pos- itron Emission Tomography for the Detection of Myocardial Viability. Eur Heart J 2001;22:1691-1701.
6. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med 1987;28:910-914.
7. Gough J, Scott-Coombes D, Fausto Palazzo F. Thyroid incidentaloma: An evidence-based assessment of management strategy. World J Surg 2008; 32:1264-1268.
8. Cohen MS, Arslan N, Dehdashti F et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 2001;130:941-946.
9. Kang KW, Kim SK, Kang HS et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 2003;88:4100-4104.
10. Chen YK, Ding HJ, Chen KT et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res 2005;25:1421-1426.
11. Kim TY, Kim WB, Ryu JS et al. 18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: High prevalence of malignancy in thyroid PET incidentaloma. Laryngoscope 2005;115:1074-1078.
12. Chu QD, Connor MS, Lilien DL et al. Positron emission tomography (PET) positive thyroid incidentaloma: The risk of malignancy observed in a tertiary referral center. Am Surg 2006;72:272-275.
13. Bogsrud TV, Karantanis D, Nathan MA et al. The value of quantifying 18FFDG uptake in thyroid nodules found incidentally on whole-body PET-CT. Nucl Med Commun 2007;28:373-381.
14. Are C, Hsu JF, Ghossein RA et al. Histological aggressiveness of fluorodeoxy glucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas. Ann Surg Oncol 2007;14:3210-3215.
15. Bae JS, Chae BJ, Park WC et al. Incidental thyroid lesions detected by FDG-PET/CT: Prevalence and risk of thyroid cancer. World J Surg Oncol 2009;7:63.
16. Zhai G, Zhang M, Xu H et al. The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography whole body imaging in the evaluation of focal thyroid incidentaloma. J Endocrinol Invest 2010;33: 151-155.
17. Ohba K, Nishizawa S, Matsushita A et al. High incidence of thyroid cancer in focal thyroid incidentaloma detected by 18F-fluorodeoxyglucose positron emission tomography in relatively young healthy subjects: Results of 3-year follow-up. Endocr J 2010;57:395-401.
18. Nakamoto Y, Tatsumi M, Hammoud D et al. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 2005;234:879-885.
19. Shie P, Cardarelli R, Sprawls K et al. Systematic review: Prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomography. Nucl Med Commun 2009;30:742-748.
20. Kang BJ, O JH, Baik JH et al. Incidental thyroid uptake on F-18 FDG PET/ CT: Correlation with ultrasonography and pathology. Ann Nucl Med 2009; 23:729-737.
21. Kurata S, Ishibashi M, Hiromatsu Y et al. Diffuse and diffuse-plus-focal uptake in the thyroid gland identified by using FDG-PET: Prevalence of thyroid cancer and Hashimoto's thyroiditis. Ann Nucl Med 2007;21:325-330.
22. Liu Y. Clinical significance of thyroid uptake on F18-fluorodeoxyglucose positron emission tomography. Ann Nucl Med 2009;23:17-23.
23. Choi JY, Lee KS, Kim HJ et al. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: Clinical significance and improved characterization. J Nucl Med 2006;47:609-615.
24. Nam SY, Roh JL, Kim JS et al. Focal uptake of (18)F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers. Clin Endocrinol (Oxf) 2007;67:135-139.
25. Traugott AL, Dehdashti F, Trinkaus K et al. Exclusion of malignancy in thyroid nodules with indeterminate fine-needle aspiration cytology after negative 18F-fluorodeoxyglucose positron emission tomography: Interim analysis. World J Surg 2010;34:1247-1253.
26. D'Souza MM, Marwaha RK, Sharma R et al. Prospective evaluation of solitary thyroid nodule on 18F-FDG PET/CT and high-resolution ultrasonography. Ann Nucl Med 2010;24:345-355.
27. Matsuzu K, Segade F, Matsuzu U et al. Differential expression of glucose transporters in normal and pathologic thyroid tissue. Thyroid 2004;14: 806-812.
28. Mian C, Barollo S, Pennelli G et al. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf) 2008; 68:108-116.
29. Kresnik E, Gallowitsch HJ, Mikosch P et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. Surgery 2003;133:294-299.
30. Are C, Hsu JF, Schoder H et al. FDG-PET detected thyroid incidentalomas: Need for further investigations? Ann Surg Oncol 2007;14:239-247.
31. Chen YK, Chen YL, Cheng RH et al. The significance of FDG uptake in bilateral thyroid glands. Nucl Med Commun 2007;28:117-122.
32. Okayasu I, Saegusa M, Fujiwara M et al. Enhanced cellular proliferative activity and cell death in chronic thyroiditis and thyroid papillary carcinoma. J Cancer Res Clin Oncol 1995;121:746-752.
33. Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodule and differentiated thyroid cancer. Thyroid 2009;19:1167-1214.
34. Law TT, Lang BH. Incidental thyroid carcinoma by FDG-PET/CT:Astudy of clinicopathological characteristics. Ann Surg Oncol 2011;18:472-478.
35. Bloom AD, Adler LP, Shuck JM. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 1993;114:728-734; discussion 734-735.
36. Utiger RD. The multiplicity of thyroid nodules and carcinomas. N Engl J Med 2005;352:2376-2378.
37. Mitchell JC, Grant F, Evenson AR et al. Preoperative evaluation of thyroid nodules with 18FDG PET/CT. Surgery 2005;138:1166-1174; discussion 1174-1175.
38. De Geus-Oei LF, Pieters GF, Bonenkamp JJ et al. 18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. J Nucl Med 2006;47:770-775.
39. Sebastianes FM, Cerci JJ, Zanoni PH et al. Role of 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab 2007;92:4485-4488.
40. Hales NW, Krempl GA, Medina JE. Is there a role for fluorodeoxyglucose positron emission tomography computed tomography in cytologically indeterminate thyroid nodules? Am J Otolaryngol 2008;29:113-118.
41. Smith RB, Robinson RA, Hoffman HT et al. Preoperative FDG-PET imaging to assess the malignant potential of follicular neoplasms of the thyroid. Otolaryngol Head Neck Surg 2008;138:101-106.
42. Kim JM, Ryu JS, Kim TY et al. 18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically diagnosed as follicular neoplasm. J Clin Endocrinol Metab 2007;92:1630-1634.
43. Lloyd RV, Erickson LA, Casey MB et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 2004;28:1336-1340.
44. Gemsenjäger E, Perren A, Seifert B et al. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg 2003;197:182-190.
45. Jeong HS, Baek CH, Son YI et al. Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: Comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol (Oxf) 2006;65:402-407.
46. Feine U, Lietzenmayer R, Hanke JP et al. Fluorine-18-FDG and iodine- 131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-1472.
47. Seo JH, Lee SW, Ahn BC et al. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: Special emphasis on using 18F-FDG PET/CT. Clin Endocrinol (Oxf) 2010;72:558-563.
48. Wang W, Macapinlac H, Larson SM et al. [18F]-2-fluoro-2-deoxy-Dglucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated thyroglobulin levels. J Clin Endocrinol Metabol 1999;84:2291-2302.
49. Esteva D, Muros MA, Llamas-Elvira JM et al. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer. Ann Surg Oncol 2009;16:2006-2013.
50. Yutan E, Clark OH. Hrthle cell carcinoma. Curr Treat Options Oncol 2001; 2:331-335.
51. Pryma DA, Schöder H, Gönen M et al. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hr̈thle cell thyroid cancer patients. J Nucl Med 2006;47:1260-1266.
52. Moog F, Linke R, Manthey N et al. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 2004;41:1989-1995.
53. Petrich T, Borner AR, Otto D et al. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002;29:641-647.
54. Chin BB, Patel P, Cohade C et al. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in welldifferentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:91-95.
55. Branstetter BF 4th, Blodgett TM, Zimmer LA et al. Head and neck malignancy: Is PET/CT more accurate than PET or CT alone? Radiology 2005; 235:580-586.
56. Razfar A, Branstetter BF 4th, Christopoulos A et al. Clinical usefulness of positron emission tomography-computed tomography in recurrent thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2010;136:120-125.
57. Lal G, Fairchild T, Howe JR et al. PET-CT scans in recurrent or persistent differentiated thyroid cancer: Is there added utility beyond conventional imaging? Surgery 2010;148:1082-1089; discussion 1089-1090.
58. Katz SC, Shaha A. PET-associated incidental neoplasms of the thyroid. J Am Coll Surg 2008;207:259-264.
59. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography scanning. J Clin Endocrinol Metabol 2006;91:498-505.
60. Ricarte-Filho JC, Ryder M, Chitale DA et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles of BRAF, PIK3CA, and AKT1. Cancer Res 2009;69:4885-4893.